MEDICATION/PSYCHOTHERAPY TAILORED TO PATIENT RESOURCES
针对患者资源量身定制的药物/心理治疗
基本信息
- 批准号:6533593
- 负责人:
- 金额:$ 46.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1997
- 资助国家:美国
- 起止时间:1997-09-30 至 2003-08-31
- 项目状态:已结题
- 来源:
- 关键词:alcoholic beverage consumption alcoholism /alcohol abuse alcoholism /alcohol abuse chemotherapy behavior therapy behavioral /social science research tag clinical research clinical trials combination therapy cooperative study data collection methodology /evaluation drug administration rate /duration dyadic interaction family structure /dynamics functional ability human subject human therapy evaluation longitudinal human study motivation naltrexone outcomes research psychological tests psychotherapy questionnaires social support network statistics /biometry taurine therapy compliance
项目摘要
DESCRIPTION: This application is a response to the RFA, 'Combined
Behavioral/Pharmacologic Treatment of Alcoholism. Although new medications
are being introduced to decrease alcohol intake in alcoholics, little is
known about how these medications actually change patterns of alcohol intake
and quality of life, what patient profile can best benefit from these
medications and what psychotherapies will ultimately optimize treatment
outcome. The specific aim of this proposal is to implement the protocol
described in the RFA to examine 1) the main effects of
medication-psychotherapy combinations on patient outcomes and 2) the
variables hypothesized to moderate patient outcome. In the proposed
randomized clinical trial, two psychotherapies differing in treatment
intensity and scope, Broad Spectrum therapy (BST) and Motivational
Enhancement therapy will be combined with four medication conditions;
Naltrexone (NTX), Acamprosate (ACA), NTX+ACA, and Placebo. Patients are
treated for six months and response to treatment is followed for an
additional one year. Primary outcome domains measured are 1) abstinence and
g and 2) psychosocial functioning. Also included in this proposal are two
pilot studies designed to address key questions regarding the implementation
of the proposed RFA protocol. Pilot 1 will develop an instrument from large
existing data sets to measure patient psychosocial resources. Pilot 2 is a
randomized six month treatment trial of NTX plus ACA vs. placebo in
alcoholics also receiving BST. Overall, we anticipate that the optimum
treatment package will be one that targets the most significant of a
patients psychosocial needs while addressing the biological aspects of
alcohol dependence via effective medication management.
In order to address the main study requirements, the proposed pilot
investigation addresses three aims: assessing the effects of combined
acamprosate and naltrexone administration, pilot testing and refinement of
BST, and development of a robust yet parsimonious measure of patient
psychosocial resources.
描述:本申请是对RFA的回应,“合并
酒精中毒的行为/药物治疗。虽然新药
正在被引入以减少酗酒者的酒精摄入量,
了解这些药物如何改变酒精摄入模式
和生活质量,什么样的患者特征可以最好地受益于这些
药物治疗和什么样的心理疗法将最终优化治疗
结果。本提案的具体目的是执行议定书
在RFA中描述,以检查1)
药物-心理治疗组合对患者结局的影响; 2)
变量假设为中度患者结局。拟议
随机临床试验,两种不同的心理疗法治疗
强度和范围,广谱治疗(BST)和动机
强化治疗将与四种药物条件相结合;
纳洛酮(NTX)、阿坎酸(ACA)、NTX+ACA和安慰剂。患者
治疗6个月,并随访对治疗的反应,
再加一年。测量的主要结果领域是1)禁欲,
(2)社会心理功能。该提案还包括两个
旨在解决执行方面关键问题的试点研究
建议的RFA协议。试点1号将从大型
现有的数据集来衡量病人的心理社会资源。飞行员2是一个
NTX加ACA与安慰剂治疗6个月的随机试验,
酗酒者也接受BST。总的来说,我们预计,
治疗方案将是一个目标,最重要的是一个
患者的心理社会需求,同时解决生物方面的问题,
通过有效的药物管理实现酒精依赖。
为了满足研究的主要要求,拟议的试点项目
调查涉及三个目标:评估联合
阿坎酸和纳曲酮给药、中试和改进
BST,并制定一个强大而节俭的衡量病人
心理社会资源。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ROBERT M SWIFT其他文献
ROBERT M SWIFT的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ROBERT M SWIFT', 18)}}的其他基金
Aripiprazole and Topiramate on Free-Choice Alcohol Use
阿立哌唑和托吡酯对自由选择饮酒的影响
- 批准号:
7496632 - 财政年份:2007
- 资助金额:
$ 46.57万 - 项目类别:
Aripiprazole and Topiramate on Free-Choice Alcohol Use
阿立哌唑和托吡酯对自由选择饮酒的影响
- 批准号:
8102027 - 财政年份:2007
- 资助金额:
$ 46.57万 - 项目类别:
Aripiprazole and Topiramate on Free-Choice Alcohol Use
阿立哌唑和托吡酯对自由选择饮酒的影响
- 批准号:
7644564 - 财政年份:2007
- 资助金额:
$ 46.57万 - 项目类别:
Aripiprazole and Topiramate on Free-Choice Alcohol Use
阿立哌唑和托吡酯对自由选择饮酒的影响
- 批准号:
7318710 - 财政年份:2007
- 资助金额:
$ 46.57万 - 项目类别:
Aripiprazole and Topiramate on Free-Choice Alcohol Use
阿立哌唑和托吡酯对自由选择饮酒的影响
- 批准号:
7881539 - 财政年份:2007
- 资助金额:
$ 46.57万 - 项目类别:
Device for Acamprosate Transcutaneous Delivery to Reduce Alcohol Consumption.
用于减少酒精消耗的阿坎酸经皮输送装置。
- 批准号:
7157433 - 财政年份:2006
- 资助金额:
$ 46.57万 - 项目类别:
MEDICATION/PSYCHOTHERAPY TAILORED TO PATIENT RESOURCES
针对患者资源量身定制的药物/心理治疗
- 批准号:
6168657 - 财政年份:1997
- 资助金额:
$ 46.57万 - 项目类别:
MEDICATION/PSYCHOTHERAPY TAILORED TO PATIENT RESOURCES
针对患者资源量身定制的药物/心理治疗
- 批准号:
6371471 - 财政年份:1997
- 资助金额:
$ 46.57万 - 项目类别: